SSTR2 and neoplasm: However, recent data suggest that it can be used as first-line therapy in patients with certain characteristics that predict resistance to first-generation somatostatin analogs.31 These criteria include T2 hyperintensity or hypointensity on MRI, low SSTR2 expression, high SSTR5 expression, substantial tumor volume, and specific genetic mutations.19 This underscores the importance of tailoring treatment approaches to individual patient profiles.